# Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

> **NCT00558467** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 63 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** pramipexole immediate release (IR)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00558467
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558467, "Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00558467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*